Gonadotropin-releasing hormone (GnRH) is a potent prometastatic factor in ovarian cancer, but the intracellular signaling events are not well understood. The classical Ga q -phospholipase C signal transduction pathway known to operate in the pituitary is not involved in GnRH actions at non-pituitary targets. Here we showed that GnRH treatment of ovarian cancer cells led to a rapid and remarkable tyrosine phosphorylation of p120 catenin (p120 ctn ), which was mediated by P-cadherin. The use of P-cadherin small interfering RNA or neutralizing antibodies to inhibit P-cadherin expression and function resulted in diminished p120 ctn activation, confirming that the effect was P-cadherin specific. On exploring how P-cadherin, which lacks intrinsic kinase activity, might regulate the activation of p120 ctn , we found that P-cadherin could induce the ligandindependent activation of insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R expression or its activity significantly inhibited GnRH-induced p120 ctn activation, and the subsequent cell migration and invasion. In addition, we showed that IGF-1R regulation by P-cadherin was associated with complex formation between IGF-1R and P-cadherin, and this regulation was also observed to be in vivo correlated with metastasis. Furthermore, using a mouse model of ovarian cancer metastasis, GnRH receptor knockdown was shown to diminish peritoneal dissemination of tumors and ascites formation. These findings suggest for the first time that GnRH can initiate an outside-in p120 ctn signal transduction through the cross-talk between P-cadherin and IGF-1R, thus providing a novel molecular mechanism by which GnRH may control the high level of aggressiveness and invasion and metastasis potential that are characteristic of ovarian cancer.
Introduction
Ovarian cancer is highly lethal and is the major form of cancer death among all gynecological malignancies. As the majority of these ovarian tumors are detected at an advanced stage with metastases present beyond the ovaries, no effective therapy is available at present, with a poor 5-year survival rate of only 16-28% (Jemal et al., 2009) . Unraveling the molecular details of ovarian cancer progression and identifying the signaling molecules and pathways involved in it may have a major impact on new therapeutic interventions.
Gonadotropin-releasing hormone (GnRH) is a decapeptide that is well known for its role in the control of pituitary gonadotropin secretion, and also has a key role in extrapituitary tissues and tumor cells, including ovarian cancer. Expression of GnRH receptor (GnRHR) has been detected in 80% primary cultures of ovarian carcinomas and ovarian carcinoma biopsy specimens (Emons et al., 1989; Irmer et al., 1995) . The prevalent expression of GnRH receptor in ovarian carcinomas supports the involvement of a GnRH regulatory system in ovarian cancer. These observations also underlie the importance of understanding the mechanisms of GnRH function in ovarian cancer. Recently, in addition to its well-documented role in regulating proliferation and cell survival, we showed for the first time that GnRH may be involved in other aspects of ovarian cancer progression, such as metastasis (Cheung et al., 2006 ). Yet, the molecular details of how GnRH controls these malignant properties are still poorly understood. Intriguingly, although GnRH signals predominantly through the classical Ga q /phospholipase C pathway in the pituitary, it is not involved in GnRH's actions at non-pituitary targets . Given the important clinical applications of GnRH analogs in cancer therapy, it is of great interest to characterize the signal transduction pathways whereby GnRH contributes to tumor growth and dissemination.
Cadherins are 120-kDa transmembrane molecules that have a major role in cell-cell adhesion and are frequently altered in tumor progression. In contrast to other carcinomas in which loss of E-cadherin is a ratelimiting step in malignant progression, the majority of highly invasive and ascitic ovarian carcinomas rarely lose complete E-cadherin expression (Wong et al., 1999; Sundfeldt, 2003) . In contrast, P-cadherin exhibits a distinct expression pattern in the development of ovarian carcinomas. Specifically, P-cadherin is undetectable in normal ovarian surface epithelium, but appears in ovarian carcinomas and increases with neoplastic progression, where it is highly expressed in ovarian cancer metastases (Wong et al., 1999; Patel et al., 2003) . Of interest, our laboratory has recently demonstrated that GnRH is a potent inducer of P-cadherin expression, and that P-cadherin overexpression is able to induce increased migratory potential of ovarian cancer cells, even in cells expressing high levels of E-cadherin, suggesting that P-cadherin may have a dominant effect over E-cadherin on the invasive phenotype in ovarian cancer (Cheung et al., 2010) . However, the nature of the P-cadherin-mediated signaling events is still largely unknown.
In this study, we show for the first time that GnRH can transduce an outside-in p120 ctn metastatic signaling cascade through the cross-talk of P-cadherin and insulin-like growth factor-1 receptor (IGF-1R). This provides an attractive mechanism whereby GnRH can affect tumor progression in ovarian cancer and may explain the highly aggressive behavior of ovarian tumors expressing these two molecules.
Results

GnRH triggers p120
ctn activation in ovarian cancer cells Cadherins can modulate signal transduction through their interacting catenins. The cadherin-associated protein, especially p120 ctn , has the potential to regulate cell motility or invasion. p120 ctn is phosphorylated at multiple tyrosine sites along its sequence, and the phosphorylation status of p120 ctn is critical for its function (Cozzolino et al., 2003) . To analyze whether GnRH might affect p120 ctn phosphorylation, p120 ctn proteins were immunoprecipitated and tyrosine phosphorylation was detected using anti-phosphotyrosine antibody. As shown in Figures 1a and b , a significant increase in p120 ctn tyrosine phosphorylation could be observed following GnRHa stimulation, and tyrosinephosphorylated p120 ctn was predominantly localized in the cytoplasm. We also showed that depletion or inhibition of P-cadherin function by small interfering RNA (siRNA) or anti-P-cadherin-blocking antibody (NCC-CAD-299) (Hodivala and Watt, 1994) abolished p120 ctn tyrosine phosphorylation by GnRHa stimulation (Figure 1c) , suggesting that the effect was P-cadherin specific. In contrast, nonspecific siRNA or control IgG had no inhibitory effect ( Figure 1c ). To further investigate a possible direct cause effect of increasing P-cadherin expression on p120 ctn , we overexpressed P-cadherin (Cheung et al., 2010) . P-cadherin overexpression showed an increased tyrosine phosphorylation (3.6-fold) ( Figure 2a ) and cytoplasmic localization of p120 ctn ( Figure 2b ). There was no effect in empty vector-transfected control cells. These results suggest a key role for P-cadherin in GnRH signaling, leading to p120 ctn activation.
P-cadherin activates p120 ctn through ligand-independent transactivation of IGF-1R As cadherins lack enzymatic activity, it is conceivable that their ability to induce phosphorylation may depend on their association with other signaling systems, such Figure 1 GnRH induces p120 ctn activation in ovarian cancer cells. (a) Total cell lysates (600 mg) or (b) cytoplasmic (600 mg) and membrane fractions (300 mg) of GnRHa-treated (0.1 nM) Caov-3 cells or (c) cells transiently transfected with either the nonspecific (NS) siRNA or P-cadherin siRNA or pretreated with control IgG or anti-P-cadherin-blocking antibody in the presence or absence of GnRHa were prepared, immunoprecipitated with anti-p120 ctn , and then subjected to immunoblot with anti-phosphotyrosine or anti-p120 ctn . Equal loading for the cytoplasmic and membrane fractions was confirmed by a-tubulin and N-cadherin, respectively. The signal intensity was determined by densitometry, and the amounts of phosphorylated p120 ctn were normalized to immunoprecipitated p120 ctn . *Po0.05, difference with control.
GnRH activation of p120 ctn signaling in ovarian cancer LWT Cheung et al as receptor tyrosine kinases (RTKs). To test this, we examined a set of inhibitors at effective concentrations that specifically inhibit various RTKs, including general RTKs (genistein), IGF-1R (AG1024), fibroblast growth factor receptor 1 (SU5402), epidermal growth factor receptor (EGFR) (AG1478) and hepatocyte growth factor receptor c-Met (K252a), which have been previously implicated in the progression and metastasis of ovarian cancer (Ellerbroek et al., 2001; Steele et al., 2001; Brokaw et al., 2007; Sawada et al., 2007) . Among these inhibitors, we found that only genistein used to block RTK or AG1024 used to inhibit IGF-1R led to a marked decrease in p120 ctn activation ( Figure 3a ) and translocation ( Figure 3b ) following GnRHa stimulation. Moreover, a significant decrease in both migration and invasion could also be observed (Figure 3c ). Similar inhibition of p120 ctn activation, relocation and subsequent migration/invasion were also observed in P-cadherin-expressing cells (Figure 4) . Blockage of p120 ctn activation, migration and invasion were also seen with the IGF-1R siRNAs on GnRHa-stimulated ( Figure 5 ) or P-cadherin-overexpressing cells (Figure 6 ), further confirming that the effects were IGF-1R specific.
To prove the IGF-1R activation, levels of phosphorylated tyrosine in IGF-1R were measured. As shown in Figure 7a , phosphorylated tyrosine levels in IGF-1R were elevated upon GnRHa stimulation. Notably, these experiments were all performed in the absence of IGF-1. P-cadherin expression or GnRH stimulation had no effect on IGF-1 mRNA levels (data not shown). Significant increase in IGF-1R phosphorylation was observed in P-cadherin-expressing cells (Figure 7b ), suggesting a ligand-independent activation of IGF-1R.
We also asked whether P-cadherin engagement is necessary for the transactivation of IGF-1R. To test this, cells were first preincubated with the anti-Pcadherin antibody before GnRHa stimulation. As shown in Figure 7a , hindering P-cadherin engagement with the function-blocking antibody greatly ablated IGF-1R activation, whereas control IgG was without effect. Similar results were observed using P-cadherin siRNA (Figure 7a ), suggesting that P-cadherin is required for this effect.
IGF-1R can signal through Src (Criswell et al., 2005) and p120 ctn is a substrate of Src (Reynolds et al., 1989) , raising the possibility that IGF-1R-induced phosphorylation of p120 ctn may occur directly through the receptor, or indirectly through activation of Src. As shown in Figure 7c , although GnRHa or IGF-1 could induce efficient phosphorylation of p120 ctn , blocking Src kinase activity had no effect. Nor was the cellular localization of p120 ctn affected. These results suggest that the modulation of p120 ctn signaling by GnRHinduced IGF-1R activation may not involve Src as an intermediate, but may signal to p120 ctn directly.
P-cadherin and IGF-1R form complexes upon GnRH stimulation
In light of the involvement of IGF-1R in P-cadherinmediated activation of p120 ctn , we decided to investigate the molecular basis of their interaction. For this, we examined whether P-cadherin and IGF-1R can associate physically. Cell lysates were immunoprecipitated with anti-IGF-1R, followed by immunoblotting with anti-Pcadherin antibody. As shown in Figure 7d Figure 2 P-cadherin regulates tyrosine phosphorylation of p120 ctn and its cytoplasmic localization. (a) Total cell lysates (600 mg) or (b) cytoplasmic (600 mg) and membrane fractions (300 mg) of Caov-3 control cells or cells stably overexpressing P-cadherin (P-cad-29) were prepared, immunoprecipitated with anti-p120 ctn , and then subjected to immunoblot with anti-phosphotyrosine or anti-p120 ctn . Equal loading for the cytoplasmic and membrane fractions was confirmed by a-tubulin and N-cadherin, respectively. The signal intensity was determined by densitometry, and the amounts of phosphorylated p120 ctn were normalized to (a) immunoprecipitated p120 ctn or (b) a-tubulin and N-cadherin. *Po0.05, difference with control.
antibody, but not in those with control IgG, which indicates that P-cadherin and IGF-1R can physically associate. Moreover, the amount of IGF-1R coimmunoprecipitating with P-cadherin was greater in GnRHatreated than in GnRHa-untreated cells, and reprobing the same blots with antibody directed against P-cadherin confirmed that the differences in IGF-1R association were not due to differences in immunoprecipitated P-cadherin ( Figure 7d ). The interaction between P-cadherin and IGF-1R was specific, as no co-immunoprecipitated IGF-1R was detected when using E-and N-cadherin antibodies ( Figure 7d ). We also examined the interaction of GnRH receptor with IGF-1R, but found no similar coprecipitation (data not shown).
To investigate whether the potential regulation of P-cadherin on IGF-1R activity also existed in vivo, we compared the levels of P-cadherin with the expression levels of phosphorylated (activated) IGF-1R in paired tissue samples of primary ovarian tumors and peritoneal metastatic lesions by immunohistochemistry. We observed that the same tumor region showing strong expression of P-cadherin also expressed phospho-IGF-1R ( Figure 7e and Table 1 ). Coexpression of P-cadherin and phospho-IGF-1R was significantly more frequent in ovarian cancer metastasis compared with the corresponding primary tumors (Table 1 ; P ¼ 0.0069). These data suggest that the in vitro regulation of IGF-1R by P-cadherin that we showed in cell cultures might be found in situ in ovarian carcinomas.
GnRH receptor inhibition effectively reduces metastasis in vivo
To test the effect of GnRH on tumor metastasis, a welldeveloped experimental metastasis mouse model was used to evaluate the effect of GnRH receptor short hairpin RNA (shRNA) against ovarian cancer cells growing in the peritoneal cavity of nude mice (Shaw et al., 2004) . As shown in Figure 8 , the tumor burden as Figure 3 IGF-1R is required for GnRH-induced activation of p120 ctn . (a) Caov-3 cells were treated with either a general RTK inhibitor (genistein, 50 mM), IGF-1R inhibitor (AG1024, 10 mM), FGF-1R inhibitor (SU5402, 50 mM), EGFR inhibitor (AG1478, 200 nM), or c-Met inhibitor (K252a, 50 nM) in the presence or absence of GnRHa (0.1 nM). Whole-cell lysates were immunoprecipitated with anti-p120 ctn and analyzed for the levels of phosphorylated and total p120 ctn by western blot. (b) Cells were fractionated and equal amounts of cytoplasmic and membrane proteins were analyzed for p120 ctn expression. Equal loading and fraction purity were confirmed by reprobing for the cytoplasmic marker protein a-tubulin and membrane marker protein N-cadherin. (c) Caov-3 and OVCAR-3 control or pretreated with the various inhibitors were collected for migration (left panel) and invasion (right panel) assays.
Results are mean ± s.d. of migrated/invaded cells of five fields of triplicate wells from three independent experiments. **Po0.005, difference with control.
GnRH activation of p120 ctn signaling in ovarian cancer LWT Cheung et al gauged by ascites volume was significantly lower in mice injected with GnRH receptor shRNA-expressing cells. There was also a significant reduction in the number and the size of tumor nodules in the GnRH receptor shRNA-treated mice. In contrast, the ascites volume and tumor nodules in nonspecific shRNA were similar to those found in the control mice (Figure 8 ), giving further support to the hypothesis that the GnRH/ GnRH receptor axis is important for ovarian cancer metastasis.
Discussion
One of the hallmarks of cancer cells is their alteration in cell-cell adhesion. Here, we demonstrate that GnRH can activate a metastatic signaling cascade, wherein Pcadherin cooperates with IGF-1R to activate p120 ctn activation and, consequently, cell motility and invasion in ovarian cancer cells. Given that P-cadherin is the major cadherin subtype in late-stage ovarian tumor cells (Patel et al., 2003) , these GnRH-mediated changes may be associated with the high degree of aggressiveness and potential for invasion and metastasis that are characteristics of ovarian carcinomas.
There are multiple mechanisms by which cadherins can modulate cell migration and invasion. We found that these phenotypic alterations activated by P-cadherin are the result of changes in the activities through p120 ctn to Rho GTPases, which are considered to have essential roles in cytoskeletal reorganization and rapid turnover of the focal adhesion, which allow cells to migrate (Nobes and Hall, 1999; Etienne-Manneville and Hall, 2002; Cheung et al., 2010) . In addition, p120 ctn in the cytoplasm or nucleus may also be an important factor in regulating genes associated with an invasive phenotype, such as matrix metalloproteinase-7, by binding to the transcriptional repressor Kaiso (Spring et al., 2005) . In this context, it is noteworthy that a correlation was observed between cytoplasmic p120 GnRH activation of p120 ctn signaling in ovarian cancer LWT Cheung et al and distant metastases in ovarian tumors (Soubry et al., 2005) . Alternatively, phosphorylation of p120 ctn is implicated in regulating E-cadherin dynamics at the plasma membrane. There may be a correlation between E-cadherin downregulation and the activation of p120 ctn , as phosphorylation of p120 ctn could terminate its interaction with E-cadherin, and thereby promote E-cadherin internalization and subsequent morphological alterations (Ishiyama et al., 2010) . Considering our recent result that GnRH induces E-to P-cadherin switching and activation of p120 ctn signaling (Cheung et al., 2010) , it raises the possibility that GnRH may regulate E-cadherin levels by controlling its internalization through p120 ctn . These observations also support our other data indicating an important role for p120 ctn in GnRH-mediated ovarian tumor progression (Cheung et al., 2010) .
In search of mechanisms underlying P-cadherin regulation of p120 ctn , we found that P-cadherin transactivated the IGF-1R. This provides a novel and attractive outside-in signaling mechanism whereby P-cadherin, which does not exhibit any enzymatic activity, can lead to p120 ctn activation. Several recent studies have shown that cadherins can interact with RTKs at the cell surface and modulate signaling pathways downstream of adherens junctions. For example, E-cadherin has been shown to interact with EGFR and modulate activation of the mitogen-activated protein kinase-ERK pathway, and N-cadherin associates with FGFR-1 to regulate FGFR-1 signaling (Pece and Gutkind, 2000; Suyama et al., 2002; Qian et al., 2004) . Our finding is the first to report the activation of an RTK by P-cadherin. We have also investigated more closely EGFR, a well-characterized invasive growth regulator and effector of E-/Ncadherin. However, we found that EGFR was not involved.
Our results also show that P-cadherin and other classical cadherins have distinct effects on RTK through distinct mechanisms. Unlike E-and N-cadherin in most cases (Pece and Gutkind, 2000; Suyama et al., 2002; Qian et al., 2004) , IGF-1R regulation by P-cadherin is ligand-independent. IGF-1R transactivation has been reported to take place in various systems by both liganddependent and ligand-independent mechanisms. For example, transactivation of the IGF-1R by steroid or peptide hormone is ligand-mediated (Liao 2003; Holzman et al., 2006) . In contrast, G-protein-coupled receptor agonists have been proposed to regulate IGF-1R through a ligand-independent mechanism (Du et al., 1996) . How P-cadherin transactivates IGF-1R is not known, but this appears to involve a complex formation between P-cadherin and IGF-1R. This finding is also GnRH activation of p120 ctn signaling in ovarian cancer LWT Cheung et al supported by our result in human ovarian cancer tissue, as per which a strong positive correlation between the expression of P-cadherin and phospho-IGF-1R was identified and was more predominant in the corresponding metastasis. The interaction between P-cadherin and IGF-1R is also especially interesting in view of the fact that IGF-1R is frequently overexpressed in ovarian cancer and confers a poor clinical prognosis (Spentzos et al., 2007) . Similar associations between IGF-1R expression and adverse prognosis are also described in other cancer models, including breast, lung and colon cancer (Dunn et al., 1998; Takahari et al., 2009; Yim et al., 2009) .
How does IGF-1R regulate the phosphorylation and function of p120 ctn ? Although p120 ctn is an excellent substrate for Src family kinases (Reynolds et al., 1989) and Src can be activated by IGF-1R (Criswell et al., 2005) , we did not find that Src inhibitor affected p120 ctn phosphorylation. Although other non-Src kinases may be involved, one possibility is that IGF-1R may phosphorylate p120 ctn directly. The presence of an interaction between P-cadherin in the cadherin/catenin complex and IGF-1R is consistent with this hypothesis, and, in fact, IGF-1R has been reported to localize at adherens junction and interact directly with the cadherin/catenin complex (Morali et al., 2001; Pennisi et al., 2002) .
Other than activating a signaling program that promotes the motile/invasive capabilities, P-cadherin, through the homophilic mechanism of heterotypic cell-cell interaction, may also facilitate the adhesion of ovarian tumor cells to the peritoneum, which is the most common avenue of metastatic dissemination of ovarian cancer. In support of this contention, P-cadherin is described as the predominant form of cadherin expressed by normal peritoneum (Chen et al., 2002) . Moreover, unlike most malignant tumors (for example, breast, lung and colon cancer), ovarian cancer metastasizes primarily by direct seeding in the peritoneal cavity rather than through the circulation. The peritoneal surface is the first to be encountered by the tumor cells, and adhesion of these metastatic cells to the peritoneum is important for ovarian cancer metastasis. Our data are in agreement with these results showing significant P-cadherin staining in ovarian cancer metastasis. Moreover, we found an increase of P-cadherin expression in the vicinity of the metastatic adenocarcinoma in the omentum or peritoneum, which was observed even on mesothelial cells, suggesting that P-cadherin may mediate tumor-mesothelial cell interaction (Supplementary Figure 1 ). In addition to the adhesive function, intimate cell-cell contacts may also facilitate juxtacrine ligand and receptor interactions (Fagotto and Gumbiner, 1996) . For example, the Jagged-1/Notch3 juxtacrine signaling has been shown to confer a selective growth advantage on the transforming ovarian cancer cells in the peritoneal microenvironment (Choi et al., 2008) .
Our results together with others support an important role of the GnRH/GnRH receptor axis in ovarian cancer metastasis. GnRH concentrations in tumor tissues have not been determined. However, it was shown that the plasma GnRH concentrations in normal women are 0.035-0.146 nM (Grzes´and Szamatowicz, 1978; Kawamura et al., 1980) . This is consistent with the dosage of GnRH (0.1 nM) used in our experiments. Alonso et al. (2004) analyzed GnRH receptor expression in 62 patients with ovarian cancer and found that 74% had a very strong expression. Wilkinson et al. (2008) had a similar observation in 138 patients; however, the prognosis of patients with a high level of GnRH receptor was favorable. These findings suggest that GnRH receptor may be a useful treatment target. Yet, although several small-sized studies of GnRH analogs have shown certain efficacy, evidence for a role in ovarian cancer treatment has not been obtained. Our finding that GnRH receptor knockdown significantly inhibited peritoneal tumor nodules GnRH induces the recruitment of IGF-1R to P-cadherin. (a) Caov-3 cells transiently transfected with either the nonspecific (NS) siRNA or P-cadherin siRNA or treated with control IgG or anti-P-cadherin-blocking antibody in the presence or absence of GnRHa (0.1 nM) or (b) Caov-3 control or P-cad-29 cells were collected and analyzed by western blot using specific antibodies to phospho (p)-IGF-1R and IGF-1R. (c) Total cell lysates (600 mg) or cytoplasmic (600 mg) and membrane fractions (300 mg) of GnRHatreated Caov-3 cells in the presence or absence of PP2 (5 mM) were prepared, immunoprecipitated with anti-p120 ctn and then subjected to immunoblot with anti-phosphotyrosine or anti-p120 ctn . Equal loading for the cytoplasmic and membrane fractions was confirmed by a-tubulin and N-cadherin, respectively. (d) In all, 600 mg of lysates of GnRHa-treated cells was immunoprecipitated with anti-IGF-1R and then subjected to immunoblot with anti-P-cadherin, anti-E-cadherin, anti-N-cadherin or anti-IGF-1R. (e) Representative staining of P-cadherin and p-IGF-1R from the same tumor samples are shown (magnification, Â 400). Sections were counterstained with hematoxylin to reveal the nuclei. and ascites formation strongly implicates its potential for clinical application. In summary, the results of this study reveal a new mechanism by which GnRH may promote the aggressive behavior of ovarian cancer. This mechanism involves P-cadherin, which cooperates with IGF-1R to alter p120 ctn signaling, ultimately enhancing tumor cell migration and invasion. Taken together with our previous studies (Cheung et al., 2006 (Cheung et al., , 2010 , our data strongly suggest the important role for GnRH in ovarian cancer metastasis and provide a mechanistic rationale for targeting GnRH receptor or its associated signaling in the treatment of metastatic ovarian cancer.
Materials and methods
Cell culture and treatments
Human ovarian cancer cell lines Caov-3 and OVCAR-3 (kindly provided by Dr N Auersperg, University of British Columbia, Vancouver, Canada) were routinely maintained at 37 1C, 5% CO 2 in medium 199:105 (Sigma, St Louis, MO, USA) supplemented with 5% fetal bovine serum and 100 U/ml penicillin-streptomycin (Invitrogen, San Diego, CA, USA). For experiments using the function-blocking antibody against P-cadherin (NCC-CAD-299) (Calbiochem, San Diego, CA, USA), cells were preincubated with the antibody (100 mg) for 1 h at 37 1C before GnRH agonist (GnRHa; D-Ala 6 ) (Sigma) addition. Nonspecific mouse immunoglobulin (IgG) was used as a control. Cells were collected at different times, lysed and immunoblotted. For inhibitor studies, cells were pretreated with genistein (50 mM), AG1024 (10 mM), AG1478 (200 nM), K252a (50 nM), SU5402 (50 mM) or PP2 (5 mM) (Calbiochem, Stay as nM for AG1478 and K252a) for 30 min at 37 1C before GnRHa stimulation.
Small interfering RNA (siRNA) transfection siRNA duplex specific to GnRH receptor (5 0 -CAAGAACA AUAUACCAAGA-3 0 ), P-cadherin (5 0 -GAGGGUGUCUUC GCUGUAG-3 0 ) or IGF-1R (5 0 -CAAGAACAAUAUACCA AGA-3 0 ) were purchased from Dharmacon (Lafayette, CO, USA). Non-targeting siRNA duplex (Dharmacon) was used as non-specific control. Transfection was performed using siLentFect (Bio-Rad, Hercules, CA, USA) according to the manufacturer's procedures.
Western blot, immunoprecipitation and cell fractionation Equal amounts of protein (40 mg) were subjected to SDS-PAGE and then transferred onto a nitrocellulose membrane. Antibodies specific for P-cadherin (1:1000), p120 ctn (1:2000) (Transduction Laboratories, Lexington, KY, USA), IGF-1R (1:1000), phospho-IGF-1R (1:1000) (Cell Signaling), phosphotyrosine (1:1000) (Upstate, Lake Placid, NY, USA) and b-actin (1:2000) (Sigma) were used. Bound proteins were detected by using appropriate horseradish peroxidase-conjugated secondary antibodies (Bio-Rad) in the enhanced chemiluminescence (Amersham, Piscataway, NJ, USA). For immunoprecipitation analysis, 600 mg of total cell lysates was precleared by incubating with 1:1 slurry of protein A/G agarose (Santa Cruz, Santa Cruz, CA, USA) for 2 h at 4 1C, and then immunoprecipitated with antibodies against p120 ctn (1 mg) or IGF-1R (1:100) overnight at 4 1C. The immune complexes were collected by incubation with protein A/G agarose for 4 h before being resolved by SDS-PAGE and immunoblotted with antibodies to phosphotyrosine or P-cadherin. Normal IgG was used as negative control. For cell-fractionation analysis, cells were fractionated into membrane, cytoplasmic or nuclear fractions using the Qproteome Cell Compartment kit (QIAGEN, Chatsworth, CA, USA). The purity of subcellular fractions was confirmed by using antibodies against N-cadherin (a membrane marker) (Transduction Laboratories) and a-tubulin (a cytoplasmic marker) (Lab Vision, Fremont, CA, USA).
Transwell migration and invasion assay Cells (1 Â 10 5 ) were seeded into the upper chamber of a Transwell insert (BD Biosciences, Palo Alto, CA, USA) in serum-free medium for 24 h, and the ability of cells to migrate through filters was assayed as previously reported by us (Cheung et al., 2006) . To assess cellular invasion, the same protocol was used, except that inserts were precoated with Matrigel (BD Biosciences, Palo Alto, CA, USA). Results were presented as the mean cell number of five fields (±s.d.) of triplicate wells from three independent experiments.
Immunohistochemistry
Immunohistochemical analysis was done on tumor tissues prepared, with Institutional Review Board approval by the Queen Mary Hospital of the University of Hong Kong. Tissue samples included 12 paired primary and metastatic ovarian cancer tissues obtained during the same surgical procedure from patients of stage III and IV ovarian cancer (7 serous, 3 endometrioid, 1 mucinous and 1 clear cell). The sections were deparaffinized with xylene and rehydrated in graded alcohol before being placed in 3% H 2 O 2 blocking solution, which was followed by antigen retrieval by boiling in Tris-EDTA buffer (pH 9). The sections were stained with either P-cadherin (BD Biosciences; 1:100) or phospho-IGF-1R (Cell Signaling; 1:50), detected by the labeled avidin-biotin system (Zymed, San Francisco, CA, USA), and counterstained with hematoxylin. Normal IgG was used as a negative control. Scoring was assigned according to the intensity and percentage of positive staining and graded negative, low or high as described (Pon et al., 2008) .
In vivo metastasis assay Lentiviruses carrying GnRH receptor or nonspecific shRNA were generated by cotransfection of 293T cells with the constructs and lentiviral packaging mix (Sigma) using Lipofectamine 2000 (Invitrogen). Conditioned media containing the infectious viral particles were collected at 48 h posttransfection and filtered through 0.4-mm filters. These particles were then used to transduce Caov-3 for 24 h, and the transfected cells were selected with 1 mg/ml puromycin. Then, 1 Â 10 7 cells were injected intraperitoneally into 4-6-week-old female BALB/c athymic mice (Charles River Laboratories, Wilmington, MA, USA) (n ¼ 3 mice per group), and the experiment was conducted twice. The care and use of animals was in accordance with institutional guidelines. The mice was monitored twice weekly for lethargy, weight loss and abdominal enlargement. Mice were killed by cervical dislocation when the tumor burden exceeded 10% of their body weight. Tumor formation was monitored over an 8-week period. After killing, ascites was quantified and the number of tumor nodules within the peritoneal cavity was counted.
Statistical analysis
Data were expressed as mean values of at least three independent experiments ± s.d. The statistical significance of differences and associations were analyzed by one-way ANOVA, followed by Tukey's least significant difference t test for post hoc analysis or the Fisher's exact test (GraphPad Software, San Diego, CA, USA). Po0.05 was considered significant.
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